Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Arthritis Care Res (Hoboken). 2019 Nov 29;72(1):9–17. doi: 10.1002/acr.23824

Table 3.

Risk of hospitalized infection in abatacept versus TNFi initiators: 1:1 PS-matched analysis

Abatacept (N=11,248) TNFi (N=11,248)
No. Events Person-Years IR, per 1000 PY (95% CI) HR (95% CI) No. Events Person-years IR, per 1000 PY (95% CI) HR (95% CI)
As-Treated (<30 days gap) 188 5,126 36.7 (31.8–42.3) 0.78 (0.64–0.95) 219 4,621 47.4 (41.5–54.1) 1.0
As-Treated (Any gap) 298
8,201 36.3 (32.4–40.7) 0.86 (0.74–1.01) 321 7,639 42.0 (37.7–46.9) 1.0